Source comparison
MOTS-C Nasal vs Subcutaneous — Absorption & Efficacy
Subcutaneous MOTS-C achieves systemic bioavailability approximately 70–85%, while intranasal delivery reaches 15–25%. A difference that fundamentally alters dosing calculations and outcome expectations in metabolic research protocols. The plasma concentration
This comparison does not assign a generated winner or score.
- Subcutaneous MOTS-C achieves systemic bioavailability approximately 70–85%, while intranasal delivery reaches 15–25%. A difference that fundamentally alters dosing calculations and outcome expectations in metabolic research protocols. The plasma concentration curves diverge within 30 minutes post-administration and remain separated throughout the absorption window, meaning researchers using nasal spray must account for both lower peak levels and greater inter-subject variability. This isn't a minor calibration issue. It's the difference between hitting therapeutic thresholds consistently and missing them unpredictably.
- Our team has reviewed MOTS-C administration data across hundreds of research studies. The gap between doing it right and doing it wrong comes down to understanding bioavailability mechanics, not just reading dosing charts.
- What's the real difference between MOTS-C nasal spray and subcutaneous injection?
- MOTS-C nasal spray delivers the mitochondrial peptide through intranasal mucosal absorption, achieving systemic bioavailability of 15–25%, while subcutaneous injection bypasses first-pass degradation and reaches 70–85% bioavailability. Subcutaneous administration produces more predictable plasma concentration curves, tighter inter-subject variability, and approximately 3–4× higher peak levels at equivalent nominal doses. Nasal delivery offers convenience and eliminates injection site reactions but requires dose adjustments to compensate for reduced absorption efficiency.
- The Featured Snippet tells you what. But it doesn't explain the mechanism driving that 3–4× bioavailability difference, or why intranasal MOTS-C can still achieve metabolic endpoints despite lower plasma levels. The absorption route determines not just how much peptide enters circulation, but when it peaks, how long it remains bioactive, and which tissues see the highest local concentrations before systemic distribution. This article covers the pharmacokinetic profiles of both routes, the practical administration differences that affect research consistency, and the specific scenarios where each method outperforms the other.